![]() ![]() Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so.Translate or authorize a translation of the Article.This means that you may not, without the prior written permission of the CUA: You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. Earlier administration of 223Ra therapy to fitter patients with mCRPC should be tested. ![]() With baseline Hb, tALP, and ECOG PS, we were able to divide patients into three groups with different median OS (months): 23.0 (95% CI 12.8–33.2), 8.0 (95% CI 6.7–9.3), and 5.0 (95% CI 3.1–6.9) for low-, intermediate-, and high-risk, respectively (p<0.001).Ĭonclusions: We found that 223Ra therapy can result in an OS of close to two years in carefully selected patients. EBRT prior and/or concurrent to 223Ra showed a trend (p=0.051) towards inferior OS by univariate analysis only. By univariate analysis (log-rank test), baseline Eastern Cooperative Oncology Group performance status (ECOG PS) 0–1 (p=0.001), ≥5 cycles of 223Ra (p<0.001), baseline hemoglobin (Hb) ≥120 g/L (p <0.001), baseline total alkaline phosphatase (tALP) <110 U/L (p=0.001), and any prostate-specific antigen (PSA) decline at week 12 (p=0.013) were associated with increased OS. Median OS was 9.0 (95% confidence interval 7.4–10.6) months. Results: A total of 133 patients were treated with 223Ra median age was 72 years. Log rank test (Kaplan-Meier method) and Cox regression analysis were used to predict overall survival (OS). Methods: We tested known and possible prognostic parameters, including palliative EBRT, both prior and concurrent to 223Ra. Introduction: We aimed to investigate several clinical and biochemical parameters, including palliative external beam radiation therapy (EBRT) to predict survival in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with radium-223 (223Ra). Radium-223 metastatic castrate-resistant prostate cancer overall survival Abstract Département de Radio-Oncologie, Centre Hospitalier de l’Université de Montréal (CHUM) - Hôpital Notre-Dame, Montréal, Québec, Canada ![]()
0 Comments
Leave a Reply. |